InnoCan Pharma Reports Impressive Preclinical Trial Results as it Eyes Expansion into $52b Veterinary Services Industry
InnoCan Pharma Corporation, an Israeli pharmaceutical technology company and pioneer in CBD-Pharma delivery systems, reported positive results in a preclinical trial on epileptic seizures in dogs using LPT. The company is conducting this research in collaboration with Yissum, the commercial arm of The Hebrew University of Jerusalem.
InnoCan Pharma is developing several novel drug delivery platforms to make use of CBD’s perceived low bioavailability with the objective of vastly improving current drug delivery mechanisms. The primary research focus of InnoCan is LPT CBD-loaded liposomes, which inject CBD directly into the bloodstream, allowing for precise dosing and prolonged and controlled release of CBD into the patient’s bloodstream. Last year, the company conducted animal trials with its CBD-loaded liposome technology (LPT), and the results revealed that the pharmacokinetic (PK), a measure of drug efficacy, in animals was identical to what was seen in a previous small animal study. This suggests that significant levels of CBD could be made available in humans and animals for an extended period of time. The successful trials enabled InnoCan to pursue the commercialization of veterinary medicine. This new market presents significant growth opportunities for the company, and InnoCan is well-positioned to reap the first-mover advantages in this market.
In this recent trial, Paco, a 9-year-old dog, was treated with LPT injections from InnoCan Pharma. Paco had drug-resistant refractory idiopathic epilepsy. Epilepsy is a chronic brain disorder characterized by unexpected and recurring seizures. Paco received several injections of the LPT drug, with a 4-week interval between injections. The results showed that the frequency and intensity of the dog’s epileptic seizures decreased significantly since the last LPT injection on April 25, and Paco has not had any seizures in over 10 weeks.
Earlier this year, InnoCan reported a successful outcome from its liposomal-CBD formulation (LPT) treatment of a dog with hip and elbow osteoarthritis as well. As reported by the dog’s owner, the treatment resulted in reduced pain and improved mobility. This is a significant step forward for the company as it works to commercialize its ground-breaking technology.
Once commercialized, the company will enter a $52 billion veterinary services market that has ample room for disruption. CBD-based veterinary pharmaceuticals are still in their early stages, so there is plenty of room for growth and expansion. Due to regulatory challenges surrounding CBD, the market is currently dominated by a few players, the majority of whom are in the early stages of research. On the other hand, InnoCan’s research has gained significant traction, and the positive results relating to the use of CBD pharma to treat critical animal illnesses have paved the way for a variety of therapy options for LPT. The global anti-epilepsy drugs market was valued at $3.49 billion in 2021 and is expected to reach $4.04 billion by 2028, growing at a compounded annual growth rate of (CAGR) of 2.12% during the forecast period.
The market is being driven forward by the increase in the number of pet ownership and pet care spending. Since the start of the pandemic, pet ownership has increased substantially and is expected to increase further over the next five years. InnoCan plans to win a significant share of this market by building long-lasting competitive advantages.
Publication Disclaimer: The author(s)/brand(s) is compensated to provide independent analysis of companies. The stock market is volatile and investors are advised to do their own research prior to making a decision. Market commentary is individual opinion and should not serve as any form of advice. You must always do your own research. “Future Markets Research Tank” and any pseudonyms or brands or accounts associated with it are digital brand names and do not seek to be any form of financial advisor or equity research organization. We may operate under a number of pseudonyms. We received monetary compensation for the content and thoughts presented above and that should be taken into account when reading any content presented. Do Not Use Any Information in Our Publications, social media channels or anything else associate with our brand to Make an Investment Decision. There is no information on our website or distributed otherwise that should be used as the basis for an investment decision. We do not act, directly or indirectly, in the capacity of any of the following and you should not construe our activities as involving any of the following: (a) investment advisor; (b) broker dealer; © broker; (d) dealer; (e) stock recommender; (f) stock picker; (g) finder; (h) securities trading expert; (i) financial planner; (j) engaging in the offer and sale of securities; (k) securities analyst; (l) financial analyst; (m) providing price targets or buy or sell recommendations. Our activities involve multiple potential and/or actual conflicts of interest — we receive monetary or securities compensation in the very securities we are promoting. The third party shareholder from which we receive compensation also has an actual conflict of interest since he or she or it is paying us securities compensation for promotion services and such non-affiliate third party shareholder may sell other shares held while we are promoting the issuer that issues the stock held by such third party shareholder. There are no implied or express warranties regarding the contents of our Publications.
